How do we treat systemic lupus erythematosus in 2024?
Abstract
In Poland, approximately 18.5 thousand people suffer from systemic lupus erythematosus (SLE) and over 4 thousand have a severe course of the disease, with involvement of internal organs. Due to the multisystem nature of the disease, care of a patient with SLE should be multidisciplinary. The aim of treatment is long-term survival of patients, protection against damage to vital organs, and optimization of quality of life. To achieve this, the goal disease should be in remission, and if this is not possible, it should have low activity. In the initial period of therapy, when internal organs are affected, it is often necessary to use intensive immunosuppression to control disease activity. Subsequently, to maintain the initial response to treatment and prevent disease relapse, less intensive immunosuppressive treatment is maintained to avoid therapy complications. Selection of appropriate medications should be individually tailored to each patient. This publication aims to present the therapeutic possibilities for SLE in 2024.
Keywords: systemic lupus erythematosusimmunosuppressive treatmentbiological drugs
Article available in PDF format
View PDFReferences
- Callen JP. Lupus erythematosus. Historical perspectives. Clin Dermatol. 1985; 3(3): 1–3.
- Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020; 172(11): ITC81–ITC96.
- Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020; 59(Suppl5): v4–vv11.
- Stajszczyk M, Majdan M, Kwiatkowska B, Batko B, Samborski W. Report of the Polish Society of Rheumatology. Systemic lupus erythematosus in Poland. Medical and social aspects of the disease and treatment strategy.
- Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023; 56: 101783.
- Ginzler EM, Antoniadis I. Clinical manifestations of systemic lupus erythematosus, measures of disease activity, and long-term complications. Curr Opin Rheumatol. 1992; 4(5): 672–680.
- Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus. Lupus Sci Med. 2015; 2(1): e000078.
- Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev. 2017; 13(3): 206–218.
- Fawzy M, Edrees A, Okasha H, et al. Gastrointestinal manifestations in systemic lupus erythematosus. Lupus. 2016; 25(13): 1456–1462.
- Sarwar S, Mohamed AS, Rogers S, et al. Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges. Cureus. 2021; 13(9): e17969.
- Yu C, Li P, Dang X, et al. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022; 132: 102871.
- Aringer M, Costenbader KH, Dörner T, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151–1159.
- Johnson SR, Aringer M, Johnson SR, et al. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Ann Rheum Dis. 2020; 79(10): 1333–1339.
- Whittall Garcia LP, Gladman DD, Urowitz M, et al. New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. Ann Rheum Dis. 2021; 80(6): 767–774.
- Kostopoulou M, Mukhtyar CB, Bertsias G, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024; 83(1): 15–29.
- Marmor MF, Kellner U, Lai TYY, et al. American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016; 123(6): 1386–1394.
- Mathian A, Arnaud L, Ruiz-Irastorza G. Is it safe to withdraw low-dose glucocorticoids in SLE patients in remission? Autoimmun Rev. 2024; 23(1): 103446.
- Rovin BH, Ayoub IM, Chan TM, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024; 105(1S): S1–S69.
- Anders HJ, Loutan J, Bruchfeld A, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. Nephrol Dial Transplant. 2023; 38(3): 551–561.
- https://www.gov.pl/web/zdrowie/choroby-nieonkologiczne.
